(Total Views: 558)
Posted On: 01/17/2021 4:16:28 PM
Post# of 153919
“Why wouldn't Leronlimab be an *almost* absolute solution in case of full approval?”
Simply because leronlimab is not an absolute solution. There’s a zero percent chance of mortality in the S/C trial control arm being reduced to zero. Like many have posted, the reduction of mortality is likely in the 30% range, meaning that S/C patients who receive leronlimab could still die. Even in the M2M population, with a larger trial, it’s unlikely that leronlimab could 100% percent reduce the progression of patients from moderate to S/C. Therefore, the drug is not an absolute solution, but part of an overall plan, in combination with vaccines and other therapeutics, to prevent the spread of, and treat active cases of, COVID19.
Simply because leronlimab is not an absolute solution. There’s a zero percent chance of mortality in the S/C trial control arm being reduced to zero. Like many have posted, the reduction of mortality is likely in the 30% range, meaning that S/C patients who receive leronlimab could still die. Even in the M2M population, with a larger trial, it’s unlikely that leronlimab could 100% percent reduce the progression of patients from moderate to S/C. Therefore, the drug is not an absolute solution, but part of an overall plan, in combination with vaccines and other therapeutics, to prevent the spread of, and treat active cases of, COVID19.
(4)
(1)
